Ensuring the safety and efficacy of injectable medications remains a top priority. One critical aspect is the detection of micro particles within liquid dosage forms. These tiny particles, although often invisible to the naked eye, can pose significant health risks to patients. Contaminants such as glass shards, silicone oil droplets, or protein aggregates may inadvertently find their way into vaccines, therapeutic proteins, or other injectables. Detecting and analyzing these particles is essential for maintaining product quality, preventing adverse reactions, and safeguarding patient well-being.
In this newsletter, we delve into the groundbreaking technology of the Bruker LUMOS II FT-IR microscope, which revolutionizes micro particle analysis. Join us as we explore how this cutting-edge instrument enhances pharmaceutical quality control and contributes to safer healthcare practices.
The LUMOS II simplifies the process of micro particle analysis, making it faster, fully automated, and more efficient. With the help of Bruker’s AI-based adaptive chemical imaging, the microscope autonomously classifies IR spectra, facilitating the detection of particulates or other contaminations.
This breakthrough technology not only enhances the quality control in pharmaceutical production but also paves the way for more innovative research in the field of particle analysis.
For a deeper dive into the LUMOS II capabilities and its impact on the industry, watch our detailed video demonstration.
More about the Bruker LUMOS II FT-IR Microscope